Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 8;606(7915):812–819. doi: 10.1038/s41586-022-04803-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 7 — (a) Treatment and sample collection timeline of HCT116 RAD21-mAID and HCT116 WAPL-mAID2 cells for high-resolution 16-fraction Repli-seq. (b-c) Propidium Iodide FACS histograms measuring DNA content for (b) HCT116 WAPL-mAID2 cells in asynchronous cultures and immediately after mitotic shake-off conditions, (c) auxin-treated HCT116 RAD21-mAID cells and HCT116 WAPL-mAID2 cells at specified time points after mitotic shake-off. No clear defect in cell cycle progression was observed. (d) Western blot of RAD21 protein in HCT116 RAD21-mAID cells for untreated control and timepoints after auxin treatment post mitotic shake off. Ponceau S stain for total protein. Blot run on one set of samples.(e) Western blot of WAPL protein in HCT116 WAPL-mAID2 cells for untreated control and timepoints after auxin treatment post mitotic shake off. Ponceau S stain for total protein. Blot run on one set of samples. (f) Total IP efficiency (genomic DNA over mitochondrial DNA) for each of 16 S phase fractions of high-resolution 16-fraction Repli-seq for HCT116 WT, HCT116 RAD21-mAID KD, and HCT116 WAPL-mAID2 KD cells.